Rachel Krupa
Overview
Explore the profile of Rachel Krupa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu D, Krupa R, Harvey M, Graf R, Schreiber N, Barnett E, et al.
J Circ Biomark
. 2021 Mar;
9:13-19.
PMID: 33717359
Introduction: Here we describe the development of a protein immunofluorescent assay for the detection of nuclear-localized androgen receptor variant 7 (AR-V7) protein within circulating tumor cells (CTCs) identified in patient...
2.
Chalfin H, Pramparo T, Mortazavi A, Niglio S, Schonhoft J, Jendrisak A, et al.
Clin Cancer Res
. 2020 Dec;
27(5):1391-1398.
PMID: 33262136
Purpose: Circulating tumor cells (CTC) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual...
3.
Fujii T, Reuben J, Huo L, Fernandez J, Gong Y, Krupa R, et al.
PLoS One
. 2017 Sep;
12(9):e0185231.
PMID: 28957377
Purpose: Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is...
4.
Lu D, Graf R, Harvey M, Madan R, Heery C, Marte J, et al.
J Circ Biomark
. 2017 Sep;
4:4.
PMID: 28936240
Retrospective analysis of patient tumour samples is a cornerstone of clinical research. CTC biomarker characterization offers a non-invasive method to analyse patient samples. However, current CTC technologies require prospective blood...
5.
Scher H, Graf R, Schreiber N, McLaughlin B, Jendrisak A, Wang Y, et al.
Cancer Res
. 2017 Aug;
77(20):5687-5698.
PMID: 28819021
The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using...
6.
Boffa D, Graf R, Salazar M, Hoag J, Lu D, Krupa R, et al.
Cancer Epidemiol Biomarkers Prev
. 2017 Apr;
26(7):1139-1145.
PMID: 28446544
Lung cancer treatment has become increasingly dependent upon invasive biopsies to profile tumors for personalized therapy. Recently, tumor expression of programmed death-ligand 1 (PD-L1) has gained interest as a potential...
7.
Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, et al.
BMC Cancer
. 2016 Sep;
16(1):744.
PMID: 27658492
Background: While programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoint inhibitors have activity in a proportion of patients with advanced bladder cancer, strongly predictive and prognostic biomarkers are...
8.
McDaniel A, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, et al.
BJU Int
. 2016 Aug;
120(5B):E30-E44.
PMID: 27539393
Objectives: To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods...
9.
Beltran H, Jendrisak A, Landers M, Mosquera J, Kossai M, Louw J, et al.
Clin Cancer Res
. 2015 Dec;
22(6):1510-9.
PMID: 26671992
Purpose: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR...
10.
Redding-Johanson A, Batth T, Chan R, Krupa R, Szmidt H, Adams P, et al.
Metab Eng
. 2011 Jan;
13(2):194-203.
PMID: 21215324
Successful metabolic engineering relies on methodologies that aid assembly and optimization of novel pathways in microbes. Many different factors may contribute to pathway performance, and problems due to mRNA abundance,...